As September 2023 comes to a close, twenty-four countries are currently reporting active outbreaks. New data show over 472,000 cholera cases were reported in 2022, an increase of 47% in one year.
While cholera is a vaccine-preventable, severe disease, there is a global shortage of oral cholera vaccines (OCV), which, according to reports, may continue for years.

For the first time, three respiratory vaccines and one Tdap combination vaccine are now approved for use by late-stage pregnant women.
On September 22, 2023, members of the U.S. CDC's Advisory Committee on Immunization Practices (ACIP) voted 11-1 to recommend a maternal respiratory syncytial virus (RSV) vaccine for pregnant women during 32 through 36 weeks gestation to protect their newborn from severe RSV illness.

Initially, when vaccines were deployed with Messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs), researchers thought it remained near the injection site and quickly degraded.
However, recent reports published by well-known clinical journals suggest that the mRNA/LNPs can enter the bloodstream, accumulate in tissues, and may be passed to infants in expressed breast milk (EBM).
To better understand how this occurrence may impact infants, a leading journal published a study supported by the Department of Pediatrics, NYU-Grossman Long Island School of Medicine.

New preclinical research from the Perelman School of Medicine at the University of Pennsylvania suggests that an innovative vaccine candidate can prevent developing Lyme disease in people.
While there are existing Lyme disease vaccines for dogs, no vaccine candidate is approved for people.

To advance the clinical research into herpes simplex virus (HSV) infections, the U.S. National Institutes of Health (NIH) today released the Strategic Plan for HSV.
An NIH-wide HSV Working Group was formed in October 2022 to develop this plan, informed by feedback from more than 100 representatives of the research and advocacy communities and stakeholders.

A new study from the Boston University (BU) School of Public Health found that 53% of dog owners expressed some Canine vaccine hesitancy (CVH) about protecting their pets from disease.
This study highlights real-world concerns, as about 45% of US households own a dog.
Pre-published in August, this September 22, 2023 analysis considers the prevalence of CVH among dog owners. As Table 3 demonstrates, a significant minority of dog owners consider vaccines administered to dogs to be unsafe (37%), ineffective (22%), and/or unnecessary (30%).

With over thirty-one countries reporting various poliovirus outbreaks in 2023, the goal of eradicating polio this year has become evasive.
Last year, the total number of poliomyelitis samples collected in countries with poliovirus transmission was 12,259 from 40  countries, an increase from 2021.
The Independent Monitoring Board (IMB) recently shared its decade-long perspective on polio eradication. When the IMB was formed, more than 90% of the burden of paralytic polio worldwide had been reduced.

With over thirty-one countries reporting various poliovirus outbreaks in 2023, the goal of eradicating polio this year has become evasive.
Last year, the total number of poliomyelitis samples collected in countries with poliovirus transmission was 12,259 from 40  countries, an increase from 2021.
The Independent Monitoring Board (IMB) recently shared its decade-long perspective on polio eradication. When the IMB was formed, more than 90% of the burden of paralytic polio worldwide had been reduced.

After three and a half years after the SARS-CoV-2 betacoronavirus began infecting people, 183 separate vaccines have entered clinical development.
Given this unprecedented response by vaccine developers, it could easily be assumed that COVID-19 vaccines have revealed all there is to know.
However, in The Lancet Respiratory Medicine, Gustavo Dayan and colleagues report the results of a phase 3 efficacy trial of a bivalent protein-based SARS-CoV-2 vaccine, offering new insights into vaccine-mediated protection against COVID-19.

When the U.S. Centers for Disease Control and Prevention (CDC) published its latest Travel Health Notice regarding countries reporting poliovirus detections.
Outbreak countries have stopped indigenous wild poliovirus but are experiencing re-infection either through the importation of wild or vaccine-derived poliovirus from another country or the emergence and circulation of vaccine-derived poliovirus.